Biology Derived Solutions

From nature to clinics to cure neuroblastoma

Keywords

  • Biotech

Industries

Biotech

Abstract

Neuroblastoma comprises 15% of cancer deaths in children. Up to 50% of high-risk cases do not respond adequately to therapy, and current therapies have a multitude of side effects.

BDS developed a panel of proteins with onco-suppressor role and a selection of peptides based on physiochemical properties (patent pending).

(Startup in formation)

Team

Dr. Francesca Pischedda, PhD
Expert scientist with special focus on cellular biology.

Prof. Giovanni Piccoli, PhD
Associate Professor in Physiology, more than 15 yrs experience in the field of neuroscience.